08:28 AM EDT, 07/13/2026 (MT Newswires) -- Goldman Sachs on Monday increased the price target for Danish biotechnology company Novonesis (NSIS-B.CO) to 495.00 Danish kroner from 475.00 kroner and reiterated its buy rating. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.